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In recent years, physiologically-based pharmacokinetic (PBPK) models have been increasingly 
used in paediatric drug development. Moreover, the value of such approach has been 
recognized by the regulatory authorities (1). 
The aim of this study was to evaluate paracetamol absorption and disposition in children 
following oral administration of sustained-release hot-melt coated (HMC) granules and tablets 
made of HMC granules (2,3) in comparison to immediate-release uncoated granules and 
tablets made of uncoated granules, using PBPK modelling. Paracetamol-specific PBPK model 
was firstly developed and validated for adults, and then extrapolated to five paediatric age 
groups: neonates/12 days, infants/18 months, children/2 years, children/6 years, and 
adolescents/12 years. Simulations were performed for fasted and fed states (different age-
appropriate meal types). The simulated plasma concentration-time profiles indicated delayed 
paracetamol absorption from HMC formulations in comparison to immediate-release 
formulations. Also, the simulations revealed that co-administration of food is not expected to 
affect paracetamol absorption following oral administration of HMC formulations, in contrast 
to immediate-release formulations whereas marked food effect was anticipated. 
According to the simulations results, HMC granules and tablets made of HMC granules can 
provide prolonged drug effect, irrespective of the presence of food, and consequently better 
compliance of paediatric patients. 
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